- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
1
Posted on 2/19/23 at 1:05 pm to ATLsuTiger
quote:
It is a sizable dilution
Wish I understood dilution better. Could you explain in simple terms?
I know the convertible securities were issued and apparently convertible into 60m shares.. but how does this “hurt” the current shareholders from a dilution perspective?
Posted on 2/19/23 at 3:36 pm to LSUcam7
The more new shares that are added, the less valuable the current ones become.
Posted on 2/19/23 at 9:14 pm to LSUcam7
Dilution - When AUPH was $7/share six years ago, the company was worth slightly more than 700 million dollars. There was 94 million shares outstanding.
Since then, the company has diluted twice to raise capital. Since there are now about 150 million shares outstanding, the company is worth about 1.2 bn at 7/share.
So a 3 bn dollar buyout only yields about 20/share whereas it would have been north of $30/share had they never diluted.
My math isn’t exact, but you get the point…
Since then, the company has diluted twice to raise capital. Since there are now about 150 million shares outstanding, the company is worth about 1.2 bn at 7/share.
So a 3 bn dollar buyout only yields about 20/share whereas it would have been north of $30/share had they never diluted.
My math isn’t exact, but you get the point…
This post was edited on 2/19/23 at 10:42 pm
Posted on 2/20/23 at 7:37 am to bayoubengals88
Yeah I guess I understand it fine.. but in the scenario of OWLT it’s definitely a lesser of two evils.
Without this dilution OWLT is likely in trouble.
Without this dilution OWLT is likely in trouble.
Posted on 2/20/23 at 10:19 am to LSUcam7
quote:Yes, dilution can be seen as a postive. Especially if the new shares have a buyer at an elevated share price.
Without this dilution OWLT is likely in trouble.
Posted on 3/7/23 at 1:48 pm to Guntoter1
Chart showing some signs of life perhaps? I'm very curious to see how they did in Q4. Anything below $14m will be a disappointment. But I'm not loving the fact that haven't even announced the earnings date yet.
Posted on 3/15/23 at 7:36 am to ATLsuTiger
Owlet had ALL of their cash in Silicon Valley Bank 
CEO says they have sorted it all out though and should be good.
Earnings call this afternoon after market close. I'm expecting $13M in Q4 revenue and a cash burn of $19M. I'm most interested in their international growth and seeing how the original Smart Sock (with notifications) is selling overseas. Obviously, any update on the FDA would be nice too but I assume that's still just a waiting game.
CEO says they have sorted it all out though and should be good. Earnings call this afternoon after market close. I'm expecting $13M in Q4 revenue and a cash burn of $19M. I'm most interested in their international growth and seeing how the original Smart Sock (with notifications) is selling overseas. Obviously, any update on the FDA would be nice too but I assume that's still just a waiting game.
Posted on 3/15/23 at 7:58 am to ATLsuTiger
Sounds like something Kurt Workman would do
Posted on 3/15/23 at 9:16 am to ATLsuTiger
Is it time to back up the truck?
Posted on 3/15/23 at 9:32 am to TDFreak
It's still a super speculative play with the FDA being involved and them needing to regain $1 minimum bid by June. Cash is tight and a reverse split is in play. The FDA 510(k) decision is pretty make or break for Owlet at this point. That said, I've already loaded up two semis worth. I'm betting on them getting FDA 510(k) clearance.
Posted on 3/15/23 at 7:49 pm to ATLsuTiger
quote:
achieved full year product portfolio revenues of $69.2 million within our targeted range
quote:
2022 gross margins were 34% and within our targeted range for the year. There were multiple factors that adversely affected gross margins in 2022, which we believe will not be present in 2023.
quote:
we adjusted our operating plan to drive the business to breakeven adjusted EBITDA in 2023. We've streamlined our organizational structure from 227 employees last year to under 100 employees today. We are targeting run rate operational expenses under $13 million in Q1, excluding stock-based compensation and adjustments and financing transaction costs.
EC transcript
Posted on 6/20/23 at 11:37 am to LSUcam7
quote:
Owlet shares are trading higher on Tuesday after the company got regulatory clearance for its BabySat medical pulse-oximetry device.
Posted on 6/20/23 at 1:10 pm to LSUcam7
quote:
Owlet shares are trading higher on Tuesday after the company got regulatory clearance for its BabySat medical pulse-oximetry device.
Finally got FDA approval and it spiked a whopping $0.20.
This post was edited on 6/20/23 at 1:17 pm
Posted on 6/20/23 at 1:39 pm to TheBoo
$69M revenue last year
Market cap still only around $52M. It’s an interesting value the market is placing on it.
$0 or $1.50 in the next 12mos IMO
Market cap still only around $52M. It’s an interesting value the market is placing on it.
$0 or $1.50 in the next 12mos IMO
Posted on 8/14/23 at 4:05 pm to LSUcam7
Financial Results for the Second Quarter Ended June 30, 2023
Revenues for the second quarter of 2023 were approximately $13.1 million.
This compares sequentially to revenues of $10.7 million in the first quarter of 2023 and $18.3 million in the second quarter of 2022.
Market cap at close was around $38.3M.
Revenues for the second quarter of 2023 were approximately $13.1 million.
This compares sequentially to revenues of $10.7 million in the first quarter of 2023 and $18.3 million in the second quarter of 2022.
Market cap at close was around $38.3M.
Posted on 8/15/23 at 8:51 am to LSUcam7
1 for 14 reverse split. Who in their right mind would go long on this?
Posted on 8/15/23 at 9:37 am to Tomatocantender
It was r/s or get delisted. There was no option. Amazon is invested here, and they appear to be making more of a push into healthcare. Who knows if they eventually take a bigger position. But I invested because I use the product for my daughter and see this category becoming much larger in the future. My daughter was sent home from the NICU with a bulky box, chest strap and wires to monitor her at home. It was the most outdated looking technology.
Owlet is the leader in the space and has a very solid brand recognition with new parents. I feel there is legit buyout potential with this one too if they get the final de novo FDA clearance. They recently got 510(k) FDA clearance, allowing them to sell a prescription version (BabySat) which will replace that old school equipment I mentioned. It also makes BabySat the first FDA cleared product in the category and validates Owlet's base technology.
The company is already being approached by DMEs, insurance companies, and health providers who are looking to cover/offer this BabySat version of the product. This will give lower income families access to this "high end" baby product. Another positive sign is that you are starting to see bigger name medical device players like Masimo who are about to enter this market of at-home pediatric health monitoring.
On the surface it was a positive earnings call yesterday, but shorty is starting to borrow my shares again. Currently tapping about 6k shares. I’m assuming they see there is still a cash crunch issue and Owlet will likely need to go to market soon to raise even more cash. They currently have about $25m in cash as of June and are burning around $11m/quarter. They also have significant dilution to come as these private placement shares (about 8m) are converted. These are some of the negatives to consider.
I think it’s going to take another year for Owlet to truly come out the other end of this thing, assuming we don’t see a full-on recession. But everything now hinges on the de novo (software as a medical device) FDA and international regulatory clearances. This brings back the main feature of the product, live o2 readings and alerts. International revenue is barely trickling in now since those regulatory bodies are following the FDA's lead, requiring medical device clearance. International revenue on pace for less than $5m in 2023. They can't continue their expansion efforts until they are fully cleared to sell the product with health alerts.
I do think the company is finally on the upswing after the FDA warning letter back in 2021, but there is still a huge hill to climb before they are in the clear financially. I'm holding what I got for now with no plans to buy or sell. The waiting game continues for Owlet investors.
Owlet is the leader in the space and has a very solid brand recognition with new parents. I feel there is legit buyout potential with this one too if they get the final de novo FDA clearance. They recently got 510(k) FDA clearance, allowing them to sell a prescription version (BabySat) which will replace that old school equipment I mentioned. It also makes BabySat the first FDA cleared product in the category and validates Owlet's base technology.
The company is already being approached by DMEs, insurance companies, and health providers who are looking to cover/offer this BabySat version of the product. This will give lower income families access to this "high end" baby product. Another positive sign is that you are starting to see bigger name medical device players like Masimo who are about to enter this market of at-home pediatric health monitoring.
On the surface it was a positive earnings call yesterday, but shorty is starting to borrow my shares again. Currently tapping about 6k shares. I’m assuming they see there is still a cash crunch issue and Owlet will likely need to go to market soon to raise even more cash. They currently have about $25m in cash as of June and are burning around $11m/quarter. They also have significant dilution to come as these private placement shares (about 8m) are converted. These are some of the negatives to consider.
I think it’s going to take another year for Owlet to truly come out the other end of this thing, assuming we don’t see a full-on recession. But everything now hinges on the de novo (software as a medical device) FDA and international regulatory clearances. This brings back the main feature of the product, live o2 readings and alerts. International revenue is barely trickling in now since those regulatory bodies are following the FDA's lead, requiring medical device clearance. International revenue on pace for less than $5m in 2023. They can't continue their expansion efforts until they are fully cleared to sell the product with health alerts.
I do think the company is finally on the upswing after the FDA warning letter back in 2021, but there is still a huge hill to climb before they are in the clear financially. I'm holding what I got for now with no plans to buy or sell. The waiting game continues for Owlet investors.
Posted on 11/13/23 at 2:40 pm to ATLsuTiger
Posted on 11/13/23 at 3:06 pm to LSUcam7
Two FDA clearances and an upcoming CE mark decision for Euro clearance. 
Man I'm so deep in this bitch that I created a Reddit community to track it. lol
The CEO will be joining us there at 7pm EST to answer retail investor questions.
Earnings call at 4:30est
r/OWLT
Man I'm so deep in this bitch that I created a Reddit community to track it. lol
The CEO will be joining us there at 7pm EST to answer retail investor questions.
Earnings call at 4:30est
r/OWLT
Page 2 of 3
Popular
Back to top
Follow TigerDroppings for LSU Football News